Urinary podocyte excretion and proteinuria in patients treated with antivascular endothelial growth factor therapy for solid tumor malignancies

Suzanne R. Hayman, Juan C. Calle, Aminah Jatoi, Iasmina M. Craici, Steven J. Wagner, Amy L. Weaver, Eddie L. Greene, Joseph Peter Grande, Vesna D Garovic

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: Urinary podocyte excretion (podocyturia) may function as a more specific marker of ongoing glomerular damage. This study sought to analyze the relationship between proteinuria and podocyturia in cancer patients treated with antivascular endothelial growth factor (anti-VEGF) agents. Methods: Thirty-seven patients treated with anti-VEGF medications were analyzed in a single-institution, cross-sectional study. Podocyte cultures were performed on random urine collections (50-100 ml), and podocytes were identified by positive podocin staining. The corresponding urine samples were analyzed for protein and creatinine (Cr) measurements. Results: Proteinuria ≥0.5 g/g Cr was found in 30% of the patients (median, 0.12; interquartile range, 0.04-0.86), and 62% had podocyturia. There was a significant difference in the amount of podocyturia between patients with proteinuria ≥0.5 g/g Cr and those with a value <0.5 g/g Cr (median podocyturia, 1.08 cells/mg Cr, range, 0-14.55 vs. 0.03 cells/mg Cr, range, 0-1.64, respectively; p < 0.001). A statistically significant correlation was observed between the cumulative dose of bevacizumab and both proteinuria (r = 0.48, p = 0.004) and podocyturia (r = 0.34, p = 0.045) as well as between proteinuria and podocyturia (r = 0.63, p < 0.001), suggesting that these are mechanistically related. Discussion: Ongoing podocyte loss may be mechanistically related to the onset and severity of proteinuria in patients treated with anti-VEGF agents.

Original languageEnglish (US)
Pages (from-to)271-278
Number of pages8
JournalOncology (Switzerland)
Volume86
Issue number5-6
DOIs
StatePublished - 2014

Fingerprint

Endothelial Growth Factors
Podocytes
Proteinuria
Creatinine
Neoplasms
Therapeutics
Urine Specimen Collection
Cross-Sectional Studies
Urine
Staining and Labeling

Keywords

  • Antivascular endothelial growth factor therapy
  • Hypertension
  • Malignancy
  • Podocyturia
  • Proteinuria

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Urinary podocyte excretion and proteinuria in patients treated with antivascular endothelial growth factor therapy for solid tumor malignancies. / Hayman, Suzanne R.; Calle, Juan C.; Jatoi, Aminah; Craici, Iasmina M.; Wagner, Steven J.; Weaver, Amy L.; Greene, Eddie L.; Grande, Joseph Peter; Garovic, Vesna D.

In: Oncology (Switzerland), Vol. 86, No. 5-6, 2014, p. 271-278.

Research output: Contribution to journalArticle

Hayman, Suzanne R. ; Calle, Juan C. ; Jatoi, Aminah ; Craici, Iasmina M. ; Wagner, Steven J. ; Weaver, Amy L. ; Greene, Eddie L. ; Grande, Joseph Peter ; Garovic, Vesna D. / Urinary podocyte excretion and proteinuria in patients treated with antivascular endothelial growth factor therapy for solid tumor malignancies. In: Oncology (Switzerland). 2014 ; Vol. 86, No. 5-6. pp. 271-278.
@article{cd45e438b11445a9a34a96345133ee0e,
title = "Urinary podocyte excretion and proteinuria in patients treated with antivascular endothelial growth factor therapy for solid tumor malignancies",
abstract = "Background: Urinary podocyte excretion (podocyturia) may function as a more specific marker of ongoing glomerular damage. This study sought to analyze the relationship between proteinuria and podocyturia in cancer patients treated with antivascular endothelial growth factor (anti-VEGF) agents. Methods: Thirty-seven patients treated with anti-VEGF medications were analyzed in a single-institution, cross-sectional study. Podocyte cultures were performed on random urine collections (50-100 ml), and podocytes were identified by positive podocin staining. The corresponding urine samples were analyzed for protein and creatinine (Cr) measurements. Results: Proteinuria ≥0.5 g/g Cr was found in 30{\%} of the patients (median, 0.12; interquartile range, 0.04-0.86), and 62{\%} had podocyturia. There was a significant difference in the amount of podocyturia between patients with proteinuria ≥0.5 g/g Cr and those with a value <0.5 g/g Cr (median podocyturia, 1.08 cells/mg Cr, range, 0-14.55 vs. 0.03 cells/mg Cr, range, 0-1.64, respectively; p < 0.001). A statistically significant correlation was observed between the cumulative dose of bevacizumab and both proteinuria (r = 0.48, p = 0.004) and podocyturia (r = 0.34, p = 0.045) as well as between proteinuria and podocyturia (r = 0.63, p < 0.001), suggesting that these are mechanistically related. Discussion: Ongoing podocyte loss may be mechanistically related to the onset and severity of proteinuria in patients treated with anti-VEGF agents.",
keywords = "Antivascular endothelial growth factor therapy, Hypertension, Malignancy, Podocyturia, Proteinuria",
author = "Hayman, {Suzanne R.} and Calle, {Juan C.} and Aminah Jatoi and Craici, {Iasmina M.} and Wagner, {Steven J.} and Weaver, {Amy L.} and Greene, {Eddie L.} and Grande, {Joseph Peter} and Garovic, {Vesna D}",
year = "2014",
doi = "10.1159/000360180",
language = "English (US)",
volume = "86",
pages = "271--278",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "5-6",

}

TY - JOUR

T1 - Urinary podocyte excretion and proteinuria in patients treated with antivascular endothelial growth factor therapy for solid tumor malignancies

AU - Hayman, Suzanne R.

AU - Calle, Juan C.

AU - Jatoi, Aminah

AU - Craici, Iasmina M.

AU - Wagner, Steven J.

AU - Weaver, Amy L.

AU - Greene, Eddie L.

AU - Grande, Joseph Peter

AU - Garovic, Vesna D

PY - 2014

Y1 - 2014

N2 - Background: Urinary podocyte excretion (podocyturia) may function as a more specific marker of ongoing glomerular damage. This study sought to analyze the relationship between proteinuria and podocyturia in cancer patients treated with antivascular endothelial growth factor (anti-VEGF) agents. Methods: Thirty-seven patients treated with anti-VEGF medications were analyzed in a single-institution, cross-sectional study. Podocyte cultures were performed on random urine collections (50-100 ml), and podocytes were identified by positive podocin staining. The corresponding urine samples were analyzed for protein and creatinine (Cr) measurements. Results: Proteinuria ≥0.5 g/g Cr was found in 30% of the patients (median, 0.12; interquartile range, 0.04-0.86), and 62% had podocyturia. There was a significant difference in the amount of podocyturia between patients with proteinuria ≥0.5 g/g Cr and those with a value <0.5 g/g Cr (median podocyturia, 1.08 cells/mg Cr, range, 0-14.55 vs. 0.03 cells/mg Cr, range, 0-1.64, respectively; p < 0.001). A statistically significant correlation was observed between the cumulative dose of bevacizumab and both proteinuria (r = 0.48, p = 0.004) and podocyturia (r = 0.34, p = 0.045) as well as between proteinuria and podocyturia (r = 0.63, p < 0.001), suggesting that these are mechanistically related. Discussion: Ongoing podocyte loss may be mechanistically related to the onset and severity of proteinuria in patients treated with anti-VEGF agents.

AB - Background: Urinary podocyte excretion (podocyturia) may function as a more specific marker of ongoing glomerular damage. This study sought to analyze the relationship between proteinuria and podocyturia in cancer patients treated with antivascular endothelial growth factor (anti-VEGF) agents. Methods: Thirty-seven patients treated with anti-VEGF medications were analyzed in a single-institution, cross-sectional study. Podocyte cultures were performed on random urine collections (50-100 ml), and podocytes were identified by positive podocin staining. The corresponding urine samples were analyzed for protein and creatinine (Cr) measurements. Results: Proteinuria ≥0.5 g/g Cr was found in 30% of the patients (median, 0.12; interquartile range, 0.04-0.86), and 62% had podocyturia. There was a significant difference in the amount of podocyturia between patients with proteinuria ≥0.5 g/g Cr and those with a value <0.5 g/g Cr (median podocyturia, 1.08 cells/mg Cr, range, 0-14.55 vs. 0.03 cells/mg Cr, range, 0-1.64, respectively; p < 0.001). A statistically significant correlation was observed between the cumulative dose of bevacizumab and both proteinuria (r = 0.48, p = 0.004) and podocyturia (r = 0.34, p = 0.045) as well as between proteinuria and podocyturia (r = 0.63, p < 0.001), suggesting that these are mechanistically related. Discussion: Ongoing podocyte loss may be mechanistically related to the onset and severity of proteinuria in patients treated with anti-VEGF agents.

KW - Antivascular endothelial growth factor therapy

KW - Hypertension

KW - Malignancy

KW - Podocyturia

KW - Proteinuria

UR - http://www.scopus.com/inward/record.url?scp=84901728046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901728046&partnerID=8YFLogxK

U2 - 10.1159/000360180

DO - 10.1159/000360180

M3 - Article

C2 - 24902997

AN - SCOPUS:84901728046

VL - 86

SP - 271

EP - 278

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 5-6

ER -